Reagan-Udall, Pfizer Testing Ways To Tap Sentinel Network Without FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
A pilot project operated by the Reagan-Udall Foundation and funded by Pfizer will evaluate ways drug companies can use FDA’s Sentinel electronic data network to conduct independent post-market safety surveillance.
You may also be interested in...
Sentinel May Expand To Generic Equivalence Studies
Tool being designed for rapid queries of US Sentinel data to consider generic drug switches, potentially spot equivalence problems.
Sentinel May Expand To Generic Equivalence Studies
Tool being designed for rapid queries of US Sentinel data to consider generic drug switches, potentially spot equivalence problems.
Sentinel Offers Drug Firms ‘Unique’ Venue For Post-Market Studies, Pfizer Says
Pfizer’s experience in piloting an approach to using US FDA’s Sentinel data network for post-market research demonstrated the feasibility and benefits of doing so.